欧盟评估由贝莱斯芽孢杆菌NRRL B-67647、短小芽孢杆菌NRRL B-67648和地衣芽孢杆菌NRRL B-67649组成的饲料添加剂对育肥鸡的安全性和有效性

 　　  2025年6月10日，据欧盟食品安全局（EFSA）消息，应欧盟委员会要求，欧盟动物饲料添加剂和产品（FEEDAP）研究小组就由贝莱斯芽孢杆菌NRRL B-67647、短小芽孢杆菌NRRL B-67648和地衣芽孢杆菌NRRL B-67649组成的饲料添加剂对育肥鸡、其他育肥家禽和观赏鸟的安全性和有效性发表科学意见。 
　　经过评估，专家小组认为在建议的使用条件下该添加剂对目标物种、消费者和环境是安全的。部分原文报道如下：
 
　　Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of Microsaf® when used as a feed additive for chickens for fattening, other poultry for fattening and ornamental birds. The product under assessment is based on viable cells/spores of Bacillus velezensis NRRL B-67647, Bacillus pumilus NRRL B-67648 and Bacillus licheniformis NRRL B-67649. The three bacterial species are considered by EFSA to be suitable for the qualified presumption of safety approach to safety assessment. As the identity of the strains was clearly established, no acquired antimicrobial resistance determinants of concern were detected and the lack of toxigenic potential was corroborated, the FEEDAP Panel considered the use of the active agents safe for the target species, consumers and the environment. Since no concerns are expected from the other components of the additive, the Panel concluded that Microsaf® is also considered safe for the target species, consumers and the environment. Regarding user safety, the additive is not irritant to the skin or eyes provided it is formulated with only calcium carbonate. The additive should be considered skin and respiratory sensitisers, and any exposure via skin or respiratory tract is considered a risk. The FEEDAP Panel concludes that the additive has the potential to improve the zootechnical performance of chickens for fattening at a proposed minimum inclusion level of 3 × 10⁷ total CFU/kg of complete feedingstuffs. These results are extrapolable to other poultry for fattening and ornamental birds. Microsaf® is compatible with diclazuril, narasin, maduramicin ammonium, salinomycin sodium, monensin sodium, robenidine hydrochloride and the combination narasin/nicarbazin, lasalocid and halofuginone.